Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two new program agreements, and advanced three programs to the next phase of development toward commercialization Willow reiterates its expectations of at least doubling its full year 2024 revenues SUNNYVALE, Calif., May 13, 2024 /CNW/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB:CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its commercial expansion. "The first quarter was marked by significant progress on our strategy to focus technical and business development efforts on our transformative BioOxi process for manufacturing corticosteroids," said Dr. Chris Savile, Willow's President & CEO. "Based on our progress, we anticipate signing a large strategic partnership in the second quarter to co-develop and commercialize the target corticosteroids that are expected to generate near-term R&D revenue and longer-term upside through commercial royalties. These new expected programs combined with our existing collaborations are expected to drive significant revenue growth during the year," continued Dr. Savile. First quarter and recent corporate highlights On January 16, 2024, Willow announced a new collaboration with Enterin, Inc., a clinical stage biopharmaceutical innovator to develop a new sustainable manufacturing route to their key intermediates and active pharmaceutical ingredients ("APIs"). Enterin is focused on development of groundbreaking therapeutics for treatment of neurodegenerative diseases including Parkinson's and Alzheimer's disease. Development is ongoing. On January 31, 2024, Willow announced a new program with a leading API manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. The API is ...